

Sep 15, 2025

Company Report | Sector: Pharmaceuticals

Gland Pharma

Moving from guarded to a more constructive view

We interacted with Gland Pharma to understand the triggers in US and Cenexi business along with longer term GLP-1 opportunity. To recap, US business would see launch of 2 key products – Dalbavancin and Norepinephrine and 5-6% volume increase that would drive growth in the range of 11%. Cenexi is expected to clock ~20% expansion on back of new ampoule line along with tech transfer projects at Herouville site. We understand new PFS line and qualification of two reinstalled lyophilizers would support revenue next fiscal even as existing capacity can lead to Euro50-55mn of quarterly revenue. EM sales would be driven by execution of CMS contract across Europe. Notably, GLP-1 opportunity would become meaningful in ex-US markets in FY28 as Gland ramps up pen/vial supplies; we still believe there are lot of moving parts with respect to US\$1/unit revenue potential from GLP-1s. Narrow our differential vs consensus but still remain ~7% below on FY27E earnings as we factor in better margin over FY26/27. Raise to ADD as our increased optimism on US business is reflected in expanded target multiple to 32x FY27E EPS.

Enoxaparin supply recovery, CGT launch to drive US business

Enoxaparin supplies would rebound after timing issue in previous quarter as some of the SKUs were not supplied. We understand most of the Rs700mn of the shortfall in Enoxaparin sales would be recovered in current quarter and sustain for rest of the fiscal. Q2 would see the launch of anti-biotic Dalbavancin and later on Gland would launch CGT designated Norepinephrine Bitartrate (for severe low blood pressure); coupled with base business volume growth of 6-7% and 5-6% from new launches, management is confident of ~11% US growth in the current fiscal.

Cenexi – Strong growth guidance retained at 20%

Reemphasizing its earlier commentary, Gland expects commencement of high-speed ampoule line at Fontenay and tech transfer at Herouville to drive 20% growth in the current fiscal. A new PFS line in early FY226 along with 2 new lyophilizers should substantially expand capacity and utilization in the following year. Overall Cenexi EBIDTA would be largely neutral as H1 loss would be offset by a positive EBIDTA in H2. Reckon new ampoule and PFS lines, reinstallation of lyophilizers would augur well for FY27 growth.

GLP-1 supply opportunity is beyond FY27

To refresh, Gland would have ~140mn unit vial/pens capacity by Mar'26 of which company intends to utilize ~20mn in FY27 as it targets the initial GLP-1 opportunity in the form of Liraglutide and Semaglutide in emerging markets. In our interaction, company did repeat pricing of US\$1 per vial though we understand the visibility of such a pricing is still reasonably uncertain, being dependent on GLP-1 supply capacity. Hence, we believe it would be only prudent to factor in bulk of capacity utilization and GLP-1 revenue from FY28 onwards.

Raise to ADD on revised earnings on back of better margin estimate

We have revised our estimates on better margin presumption and less of revenue changes across geography resulting in 6/7% upgrade to FY26/27 EPS estimates. While we had outlined likelihood of limited scope for upgrades in our previous update, current changes reflect a narrowing in ours vs street expectations and we still remain ~7% below FY27E consensus. With more confidence on US growth, we expand the premium to other generic plays and assign 32x multiple to derive a revised TP Rs2,250 (earlier Rs1,800) and would view Gland as a better proxy on US generics in the near term.

Reco	:	ADD
CMP	:	Rs 2,021
Target Price	:	Rs 2,250
Potential Return	:	11.5%

Stock data (as on Sep 12, 2025)

Nifty	25,114
52 Week h/l (Rs)	2131 / 1278
Market cap (Rs/USD mn)	333006 / 3772
Outstanding Shares (mn)	165
6m Avg t/o (Rs mn):	487
Div yield (%):	1.2
Bloomberg code:	GLAND IN
NSE code:	GLAND

Stock performance



Shareholding pattern (As of Mar'25 end)

Promoter	51.8%
FII+DII	40.3%
Others	8.9%

△ in instance

(1-Yr)	New	Old
Rating	ADD	NEUTRAL
Target Price	1,800	2,250

△ in earnings estimates

	FY26E	FY27E
EPS (New)	57.2	69.3
EPS (Old)	54.0	64.7
% change	5.9%	7.2%

Financial Summary

(Rs mn)	FY25	FY26E	FY27E
Net Revenue	56,165	63,340	71,245
YoY Growth	-0.9	12.8	12.5
EBIDTA	12,689	16,015	18,936
YoY Growth	-4.8	26.2	18.2
PAT	6,985	9,419	11,418
YoY Growth	(9.6)	34.8	21.2
ROE	7.8	10.0	11.3
EPS	42.4	57.2	69.3
P/E	47.6	35.3	29.1
BV	555.6	591.5	639.6
EV/EBITDA	24.5	19.3	16.1

BHAVESH GANDHI


Lead Analyst



① +91 22 6992 2934 / 35 / 36


STORY IN CHARTS

Exhibit 1: US revenue growth - FY26/27




Source: Company, YES Sec

Exhibit 2: FY26E growth driven by Cenexi @20%




Source: Company, YES Sec

Exhibit 3: Cenexi revenue estimate




Source: Company, YES Sec

Exhibit 4: Trend in US profit/milestone share




Source: Company, YES Sec

Exhibit 5: EM revenue growth forecast



Source: Company, YES Sec

Exhibit 6: FY27E margin to get push from Cenexi



Source: Company, YES Sec

FINANCIALS

Exhibit 7: Balance sheet

Y/e 31 Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
Equity capital	165	165	165	165	165
Reserves	79,423	87,074	91,343	97,262	105,181
Net worth	79,587	87,238	91,507	97,427	105,345
Debt	55	3,189	2,945	2,945	2,945
Def tax lia	842	2,201	2,148	2,148	2,148
Total liabilities	80,484	92,629	96,601	102,520	110,439
Fixed Asset	17,481	41,846	42,976	42,153	41,166
Investments	1,064	7,800	921	921	921
Net Working Capital	61,713	42,478	52,183	58,925	67,831
Inventories	19,453	16,552	16,852	19,005	21,377
Sundry debtors	8,714	15,587	15,165	17,103	19,237
Cash	37,703	18,404	25,564	26,363	30,948
Other current assets	3,134	5,918	10,250	11,401	12,824
Sundry creditors	(5,874)	(7,677)	(8,204)	(9,252)	(10,407)
Other CL	(1,418)	(6,306)	(7,444)	(5,695)	(6,148)
Def tax assets	225	504	521	521	521
Total Assets	80,484	92,629	96,601	102,520	110,439

Exhibit 8: Income statement

Y/e 31 Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
Revenue	36,246	56,647	56,165	63,340	71,245
Operating profit	10,248	13,331	12,689	16,015	18,936
Depreciation	(1,467)	(3,446)	(3,779)	(3,963)	(4,187)
Interest expense	(74)	(262)	(420)	(401)	(401)
Other income	2,405	1,702	2,136	2,200	2,200
Profit before tax	11,111	11,325	10,627	13,851	16,548
Taxes	(2,735)	(3,601)	(3,641)	(4,432)	(5,130)
Adj. profit	8,375	7,724	6,985	9,419	11,418
MI	(565)	-	-	-	-
Net profit	7,811	7,724	6,985	9,419	11,418

Exhibit 9: Cash flow statement

Y/e 31 Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
Profit before tax	11,111	11,325	10,627	13,851	16,548
Depreciation	1,467	3,446	3,779	3,963	4,187
Def tax assets (net)	(211)	1,080	(69)	-	-
Tax paid	(2,735)	(3,601)	(3,641)	(4,432)	(5,130)
Working capital Δ	(3,793)	(64)	(2,545)	(5,943)	(4,321)
Other operating items	(565)	-	-	-	-
Operating cashflow	5,275	12,187	8,149	7,439	11,284
Capital expenditure	(2,019)	(27,811)	(4,908)	(3,141)	(3,200)
Free cash flow	3,255	(15,624)	3,241	4,298	8,084
Equity raised	201	3,814	783	0	0
Investments	1,772	(6,736)	6,879	-	-
Debt financing/disposal	(7)	3,134	(244)	-	-
Dividends paid	-	(3,887)	(3,500)	(3,500)	(3,500)
Net Δ in cash	5,221	(19,299)	7,160	799	4,585

Exhibit 10: Du Pont Analysis

Y/e 31 Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
Tax burden (x)	0.75	0.68	0.66	0.68	0.69
Interest burden (x)	0.99	0.98	0.96	0.97	0.98
EBIT margin (x)	0.31	0.20	0.20	0.23	0.24
Asset turnover (x)	0.44	0.59	0.52	0.55	0.59
Financial leverage (x)	1.10	1.16	1.22	1.21	1.20
RoE (%)	11.1	9.3	7.8	10.0	11.3

Exhibit 11: Ratio analysis

Y/e 31 Mar	FY23	FY24	FY25	FY26E	FY27E
Growth matrix (%)					
Revenue growth	(17.6)	56.3	(0.9)	12.8	12.5
Op profit growth	(32.1)	30.1	(4.8)	26.2	18.2
EBIT growth	(31.1)	3.6	(4.7)	29.0	18.9
Net profit growth	(35.5)	(1.1)	(9.6)	34.8	21.2
Profitability ratios (%)					
OPM	28.3	23.5	22.6	25.3	26.6
EBIT margin	30.9	20.5	19.7	22.5	23.8
Net profit margin	23.1	13.6	12.4	14.9	16.0
RoCE	14.6	13.4	11.7	14.3	15.9
RoNW	11.1	9.3	7.8	10.0	11.3
RoA	10.1	8.0	6.4	8.2	9.4

Y/e 31 Mar	FY23	FY24	FY25	FY26E	FY27E
Per share ratios					
EPS	50.9	46.9	42.4	57.2	69.3
Dividend per share	0.0	20.0	18.0	18.0	18.0
Cash EPS	59.8	67.8	65.3	81.2	94.7
Book value per share	483.2	529.7	555.4	591.3	639.4
Valuation ratios (x)					
P/E	42.6	43.1	47.6	35.3	29.1
P/BV	4.2	3.8	3.6	3.4	3.2
M Cap/Sales	9.2	5.9	5.9	5.3	4.7
EV/EBIDTA	28.8	23.8	24.5	19.3	16.1
Payout (%)					
Tax payout	24.6	31.8	34.3	32.0	31.0
Dividend payout	0.0	50.3	50.1	37.2	30.6
Liquidity ratios					
Debtor days	88	100	99	99	99
Inventory days	196	107	110	110	110
Creditor days	59	49	53	53	53

STANDARD DISCLAIMER:

YES Securities (India) Limited, Registered Address: 2nd Floor, North Side, YES BANK House, Off Western Express Highway, Santacruz East, Mumbai - 400055. Maharashtra, India | **Correspondence Add:** 7th Floor, Urmi Estate Tower A, Ganpatrao Kadam Marg, Opp. Peninsula Business Park, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. | Website: www.yesinvest.in | Email: customer.service@ysil.in

Registration Nos.: CIN: U74992MH2013PLC240971 | SEBI Registration No.: NSE, BSE, MCX & NCDEX : INZ000185632 | Member Code: BSE – 6538, NSE – 14914, MCX – 56355 & NCDEX – 1289 | CDSL & NSDL: IN-DP-653-2021 | RESEARCH ANALYST: INH000002376 | INVESTMENT ADVISER: INA000007331 | Sponsor and Investment Manager to YSL Alternates Alpha Plus Fund (Cat III AIF) and YES Wealth Maximiser AIF (Cat III AIF) SEBI Registration No.: IN/AIF3/20-21/0818 | AMFI ARN Code – 94338

Details of Compliance Officer: Aditya Goenka | Email: compliance@ysil.in / Contact No.: 022-65078127 | **Grievances Redressal Cell:** customer.service@ysil.in / igc@ysil.in

Standard Disclaimer: Investment in securities market are subject to market risks; read all the related documents carefully before investing. Above representation provides an overview related to our past performance neither does it provide any guarantee of future performance, nor we are ensuring any guaranteed returns. Actual Client returns may vary depending upon time premium, volatility Index, intrinsic value of the script, open interest, other geopolitical conditions and choice of the customer to execute the recommendation in full or part. All recommendations are published under Research Analyst License of YES Securities (India) Limited (YSIL); execution of the recommendation is at complete discretion of customer without any intervention by the research publisher.

Contents which are exclusively for Non-Broking Products/Services e.g. Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the YSIL is just a distributor. These are not Exchange traded product and the YSIL is just acting as distributor. Kindly note that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.

YSIL is a owned subsidiary of YES Bank Limited. Savings, Current, PIS and Demat Account are offered by YES Bank Limited. Please note Brokerage would not exceed the SEBI prescribed limit. YSIL also acts in the capacity of distributor for Products such as IPOs, Mutual Funds, Mutual Fund-SIPs, NCD/Bonds, etc., All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.

Margin Trading Funding (MTF) is an exchange approved product offered to YSIL trading account holders, as per the regulation and guideline of SEBI Circular: CIR/MRD/DP/54/2017 dated June 13, 2017. For product specification, T&C, rights and obligations statement issued by the YSIL visit https://yesinvest.in/standard_documents_policies

DISCLAIMER

Investments in securities market are subject to market risks, read all the related documents carefully before investing.

The information and opinions in this report have been prepared by YSIL and are subject to change without any notice. The report and information contained herein are strictly confidential and meant solely for the intended recipient and may not be altered in any way, transmitted to, copied or redistributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of YSIL.

The information and opinions contained in the research report have been compiled or arrived at from sources believed to be reliable and have not been independently verified and no guarantee, representation of warranty, express or implied, is made as to their accuracy, completeness, authenticity or validity. No information or opinions expressed constitute an offer, or an invitation to make an offer, to buy or sell any securities or any derivative instruments related to such securities. Investments in securities are subject to market risk. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Investors should note that Price of each of the securities or value may rise or fall and, accordingly, investors may even receive amounts which are less than originally invested. The investor is advised to take into consideration all risk factors including their own financial condition, suitability to risk return profile and the like, and take independent professional and/or tax advice before investing. Opinions expressed are our current opinions as of the date appearing on this report. Investor should understand that statements regarding future prospects may not materialize and are of general nature which may not be specifically suitable to any particular investor. Past performance may not necessarily be an indicator of future performance. Actual results may differ materially from those set forth in projections. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. YES Securities (India) Limited conforms with the rules and regulations enumerated in the Securities and Exchange Board of India (Research Analysts) Regulations, 2014 as amended from time to time.

Technical analysis reports focus on studying the price movement and trading turnover charts of securities or its derivatives, as opposed to focussing on a company's fundamentals and opinions, as such, may not match with reports published on a company's fundamentals.

YSIL, its research analysts, directors, officers, employees and associates accept no liabilities for any loss or damage of any kind arising out of the use of this report. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject YSIL and associates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

YES Securities (India) Limited distributes research and engages in other approved or allowable activities with respect to U.S. Institutional Investors through Rule 15a-6 under the Securities Exchange Act of 1934 (the "Exchange Act")^[1] and regulations under an exclusive chaperone arrangement with Brasil Plural Securities LLC. The views and sentiments expressed in this research report and any findings thereof accurately reflect YES Securities (India) Limited analyst's truthful views about the subject securities and/or issuers discussed herein. YES Securities (India) Limited is not registered as a broker-dealer under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and is not a member of the Securities Investor Protection Corporation ("SIPC"). Brasil Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC. For questions or additional information, please contact Gil Aikins (gil.aikins@brasilplural.com) or call +1 212 388 5600.

This research report is the product of YES Securities (India) Limited. YES Securities (India) Limited is the employer of the research analyst(s), the authors of this research report. YES Securities (India) Limited is the concerned representatives (employees) of YES Securities (India) Limited, are responsible for the content of this research report including but not limited to any material conflict of interest of YES Securities (India) Limited in relation to the issuer(s) or securities as listed in this research report. This YES Securities (India) Limited research report is distributed in the United States through Brasil Plural Securities LLC (BPS). The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and is/are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. As per SEC Rule 15a-6, the U.S. broker-dealer must accompany any third party research report it distributes with, or provide a web address that directs a recipient to, disclosure of any material conflict of interest that can reasonably be expected to have influenced the choice of a third-party research report provider or the subject company of a third-party research.

FINRA Rules 2241 and 2242, which govern the conduct of research analysts and the content of equity and debt research reports, respectively, apply to all research distributed by a FINRA member firm, including research prepared by a foreign broker-dealer under Rule 15a-6.

- Research reports prepared by a foreign broker-dealer and distributed by a U.S. broker-dealer are deemed to be third party research reports, as reports produced by a person other than a FINRA member.
- Prior to distributing any third party research, a U.S. broker-dealer must assure that such report contains the required disclosures under FINRA Rule 2241(h) or 2242(g)(3), as applicable.

This report is intended for distribution by YES Securities (India) Limited only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). As per Rule 15a-6(b)(4) of the Exchange Act, 1934, "Major U.S. institutional investor" means a U.S. institutional investor with assets, or assets under management, in excess of US\$100 million, or a registered investment adviser with assets under management in excess of US\$100 million. If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person or entity. Transactions in securities discussed in this research report should be effected through Brasil Plural Securities LLC (BPS) or another U.S. registered broker dealer/Entity as informed by YES Securities (India) Limited from time to time.

^[1] Rule 15a-6 under the Securities Exchange Act of 1934 provides conditional exemptions from broker-dealer registration for foreign broker-dealers that engage in certain specified activities involving U.S. investors. These activities include:

- (a) Effecting unsolicited securities transactions;
- (b) Providing research reports to major U.S. institutional investors, and effecting transactions in the subject securities with or for those investors;
- (c) Soliciting and effecting transactions with or for U.S. institutional investors or major U.S. institutional investors through a "chaperoning broker-dealer"; and
- (d) Soliciting and effecting transactions with or for registered broker-dealers, banks³ acting in a broker or dealer capacity, certain international organizations, foreign persons temporarily present in the U.S., U.S. citizens resident abroad, and foreign branches and agencies of U.S. persons.

In adopting Rule 15a-6, the SEC sought "to facilitate access to foreign markets by U.S. institutional investors through foreign broker-dealers and the research that they provide, consistent with maintaining the safeguards afforded by broker-dealer registration." [Rule 15a-6 Adopting Release at 54 FR 30013; see also Registration Requirements for Foreign Broker-Dealers, Exchange Act Release No. 25801 (June 14, 1988), 53 FR 23645 (June 23, 1988)].

DISCLOSURE OF INTEREST

Name of the Research Analyst : Bhavesh Gandhi

The analyst hereby certifies that opinion expressed in this research report accurately reflect his or her personal opinion about the subject securities and no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendation and opinion expressed in this research report.

Sr. No.	Particulars	Yes/No
1	Research Analyst or his/her relative's or YSIL's financial interest in the subject company(ies)	No
2	Research Analyst or his/her relative or YSIL's actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the research report	No
3	Research Analyst or his/her relative or YSIL has any other material conflict of interest at the time of publication of the research report	No
4	Research Analyst has served as an officer, director or employee of the subject company(ies)	No
5	YSIL has received any compensation from the subject company in the past twelve months	No
6	YSIL has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
7	YSIL has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
8	YSIL has received any compensation or other benefits from the subject company or third party in connection with the research report	No
9	YSIL has managed or co-managed public offering of securities for the subject company in the past twelve months	No
10	Research Analyst or YSIL has been engaged in market making activity for the subject company(ies)	No

Since YSIL and its associates are engaged in various businesses in the financial services industry, they may have financial interest or may have received compensation for investment banking or merchant banking or brokerage services or for any other product or services of whatsoever nature from the subject company(ies) in the past twelve months or associates of YSIL may have managed or co-managed public offering of securities in the past twelve months of the subject company(ies) whose securities are discussed herein.

Associates of YSIL may have actual/beneficial ownership of 1% or more and/or other material conflict of interest in the securities discussed herein.

RECOMMENDATION PARAMETERS FOR FUNDAMENTAL REPORTS

Analysts assign ratings to the stocks according to the expected upside/downside relative to the current market price and the estimated target price. Depending on the expected returns, the recommendations are categorized as mentioned below. The performance horizon is 12 to 18 months unless specified and the target price is defined as the analysts' valuation for a stock. No benchmark is applicable to the ratings mentioned in this report.

BUY: Upside greater than 20% over 12 months

ADD: Upside between 10% to 20% over 12 months

NEUTRAL: Upside between 0% to 10% over 12 months

REDUCE: Downside between 0% to -10% over 12 months

SELL: Downside greater than -10% over 12 months

NOT RATED / UNDER REVIEW

BHAVESH
INDRAVADAN GANDHI
Analyst Signature
INDRAVADAN GANDHI
Digitally signed by BHAVESH
INDRAVADAN GANDHI
Date: 2025.09.15 00:37:52
+05'30'

ABOUT YES SECURITIES (INDIA) LIMITED

YES Securities (India) Limited ("YSIL") is a owned subsidiary of YES BANK LIMITED. YSIL is a Securities and Exchange Board of India (SEBI) registered Stock broker holding membership of National Stock Exchange (NSE), Bombay Stock Exchange (BSE), Multi Commodity Exchange (MCX) & National Commodity & Derivatives Exchange (NCDEX). YSIL is also a SEBI-registered Category I Merchant Banker, Investment Adviser and Research Analyst. YSIL is also a Sponsor and Investment Manager of Alternate Investment Fund - Category III (YSIL Alternates) and AMFI registered Mutual Fund Distributor. The Company is also a registered Depository Participant with CDSL and NSDL. YSIL offers, inter alia, trading/investment in equity and other financial products along with various value added services. We hereby declare that there are no disciplinary actions taken against YSIL by SEBI/Stock Exchanges.